logo
logo
AMN Healthcare Services, Inc.

AMN Healthcare Services, Inc.

NYSE•AMN
CEO: Ms. Caroline Sullivan Grace
セクター: Healthcare
業種: Medical - Care Facilities
上場日: 2001-11-13
AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment offers travel nurse staffing, labor disruption staffing, local staffing, international nurse and allied permanent placement, and allied staffing solutions. The Physician and Leadership Solutions segment provides locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement solutions. The Technology and Workforce Solutions segment offers language services, vendor management systems, workforce optimization, and outsourced solutions. The company also provides allied health professionals, such as physical therapists, respiratory therapists, occupational therapists, medical and radiology technologists, lab technicians, speech pathologists, rehabilitation assistants, and pharmacists. It offers its services under the brands, including AMN Healthcare, Nursefinders, HealthSource Global Staffing, O'Grady Peyton International, Connetics, Medical Search International, DRW Healthcare Staffing, and B.E. Smith. AMN Healthcare Services, Inc. was founded in 1985 and is headquartered in Dallas, Texas.
連絡先情報
8840 Cypress Waters Boulevard, Suite 300, Dallas, TX, 75019, United States
866-871-8519
www.amnhealthcare.com
時価総額
$624.22M
PER (TTM)
-2.3
16.8
配当利回り
--
52週高値
$30.49
52週安値
$14.87
52週レンジ
9%
順位24Top 10.8%
5.7
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 5.7 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$634.50M-7.71%
直近4四半期の推移

EPS

$0.76+322.22%
直近4四半期の推移

フリーCF

$14.76M-68.89%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Goodwill Impairment Loss Physician Solutions recorded $109.5M goodwill impairment loss due to lower volume and margin pressures in staffing segment.
Smart Square Sale Gain Recognized preliminary $39.2M gain from July 1, 2025 sale of Smart Square scheduling software business operations.
Nine Month Revenue Decline Total revenue fell 12% to $1,982.2M for nine months ended September 30, 2025, driven by Nurse Solutions.
Gross Margin Compression Noted Consolidated gross margin compressed to 29.2% from 31.1% due to higher provider pay packages and pricing pressure.

リスク要因

Significant Net Loss Nine months resulted in net loss of $(88.0M) compared to $40.6M net income last year, reflecting impairments.
Staffing Volume Decreasing Travel nurse demand declined, impacting Nurse Solutions revenue, while language services pricing pressure continues.
Operating Cash Flow Down Net cash provided by operating activities decreased to $193.9M for nine months versus $247.6M prior year period.

見通し

Debt Refinancing Completed Issued $400.0M 2031 Notes and amended credit facility; redeemed $500.0M 2027 Notes in October 2025.
Liquidity Sufficient Forecast Cash from operations and available credit expected to fund operations and liquidity requirements beyond the next 12 months.
Evolving Staffing Models Clients focus on permanent staff and alternative models, decreasing reliance on contingent labor post-pandemic environment.

同業比較

売上高 (TTM)

AMN Healthcare Services, Inc.AMN
$2.72B
-11.4%
Evolent Health, Inc.EVH
$2.05B
-16.6%
Nutex Health Inc.NUTX
$981.20M
+236.0%

粗利益率 (最新四半期)

Iovance Biotherapeutics, Inc.IOVA
97.9%
+65.9pp
Myriad Genetics, Inc.MYGN
69.9%
-0.3pp
Ginkgo Bioworks Holdings, Inc.DNA
67.0%
-21.7pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
INNV$1.13B-275.4-1.7%22.2%
PNTG$1.11B41.48.7%40.2%
VIR$1.04B-2.1-50.8%9.8%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-4.8%
横ばい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年2月19日
|
EPS:$0.22
|
売上高:$723.11M
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月7日|
    売上高: $634.50M-7.7%
    |
    EPS: $0.76+322.2%
    予想を上回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月8日|
    売上高: $658.18M-11.1%
    |
    EPS: $-3.02-802.3%
    予想を下回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月9日|
    売上高: $689.53M-16.0%
    |
    EPS: $-0.03-106.3%
    予想を下回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月21日|
    売上高: $2.98B-21.3%
    |
    EPS: $-3.85-171.6%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月8日|
    売上高: $687.51M-19.4%
    |
    EPS: $0.18-87.1%
    予想を下回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月9日|
    売上高: $740.69M-25.3%
    |
    EPS: $0.43-72.4%
    予想を下回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月10日|
    売上高: $820.88M-27.1%
    |
    EPS: $0.45-77.8%
    予想を下回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月22日|
    売上高: $3.79B-27.7%
    |
    EPS: $5.38-46.0%
    予想を上回る